



Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules

Nîmes, 20 February 2014 – Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases announces it has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules.

Levetiracetam micro-granules is an original formulation developed by Desitin. The small size (2 mm) of the granules makes them easy to swallow for young children or elderly people. Levetiracetam is indicated in the treatment of partial epilepsy, juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy. Four dosages will be marketed, 250 mg, 500 mg, 750 mg and 1000 mg.

This product is already available in many European markets including Germany, Great Britain, Spain, Portugal, Switzerland, Norway and Sweden. It is a great success towards patients who found the current big tablets of Levetiracetam difficult to swallow. Once registered, Advicenne will market the product on the French territory.

Doctor Luc-André Granier, founder and CEO of Advicenne, is delighted with the signature of this commercial agreement, which is the second signed in 2013 by Advicenne. A first agreement on an anti-epileptic treatment available in a form that is suitable for children has been signed on June 5, 2013 with another company: “The signature of these two agreements is a huge step forward for Advicenne. Both products fill the needs and expectation of patients and practitioners and show a perfect fit with the portfolio of neurological products developed by Advicenne. We are proud and happy to collaborate with Desitin.”

The Hamburg-based company is recognized as one of the largest pharmaceutical companies specialized in epilepsy. Desitin also develops and markets drugs for Parkinson's disease.

###

For further information, please contact:

Advicenne

LA Granier, S Delbaere, J Rachline

info@advicenne.com

+33 (0)4 66 05 54 20

About Advicenne

Advicenne is a late-stage biopharmaceutical company focusing on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company has a strong portfolio of products in late-stage development targeting critical unmet needs in nephrology and neurology. Advicenne also develops a clinical and pre-

clinical pipeline of potential treatments for additional orphan diseases in collaboration with Key Opinion Leaders.

The Company was established in 2007 in Nimes (France). Since its inception, the Company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.